Navigation Links
Virus Level could Predict Cervical Cancer Risk,,

Cervical cancer is one of the most common cancers in women. If it is caught and treated early, it is curable in most cases.// The Pap smear is the standard screening method for the disease. It is used to detect unusual, precancerous changes in cervical cells. Two strains of the human papilloma virus (HPV) are associated with an increased chance of getting the cancer, but not all women who test positive, develop the disease. Swedish researchers say that measuring the levels of a virus linked to cervical cancer could help to identify women at risk from the disease long before it develops or is detected with conventional screening. New research published in The Lancet medical journal suggests that the amount of one strain of the virus, called HPV-16, could be a more accurate predictor of the disease. 'High amounts of HPV 16 DNA is a major risk factor for development of cervical carcinoma (cancer),' said Agnetha Josefsson and scientists at the University of Uppsala. Dr Peter Sasieni, of Britain's Imperial Cancer Research Fund, said the research underlined the key role that HPV infection plays in the development of cervical cancer. He said, 'The results show that women with low levels of infection are at extremely low risk of developing cervical cancer within 10 years, the implications are that women with low levels of the virus could be safely monitored by regular repeat testing, rather than being referred directly to a gynecologist,'
'"/>




Page: 1

Related medicine news :

1. Ebola Virus - Outbreak Claims More Lives In Uganda.
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Virus Combats Brain Tumour
4. Virus killer
5. Pain Killers Keep the Virus Away
6. Measles Suppresses AIDS Virus
7. Virus connection to cervical injury
8. Virus Helps Remove Brain Cancer
9. Origin Of SARS Virus Discovered
10. New Molecule that can stop the growth of Viruses
11. The Possibility Of Fighting HIV with Another Virus Questioned
Post Your Comments:
(Date:5/16/2008)...be the fastest growing industry, but it has been s...t fast food chains are now entirely automated, mos...heir records on paper. , In a new position paper...d/policy/ehealth.pdf ) released today by the Ameri...est medical specialty organization says that colla...
(Date:5/16/2008)...ater: An AIDS Vaccine is Possible and,Still Urgent...ire/ -- Twenty-five years since the,discovery of H...dressing,the AIDS pandemic. Scientists have learne... any other pathogen, and have developed more drugs...ned. But this progress is not,enough. While it is ...
(Date:5/16/2008)...lly Residents to Eat Right, Move More and ... 16 /PRNewswire/ -- The last decade can be defined...ich seem to go in and out of,fashion like shoulder...n,slim. Two out of three Americans -- including 30...t or obese., A new campaign crossing the country,...
(Date:5/16/2008)...cells in cord blood more than 30-fold , ,...t uses natural killer (NK) immune system cells fro...leukemia cells in mice, researchers say. , The...n acute lymphocytic leukemia (ALL) and acute myelo...essive human leukemias, according to the study. ,...
Breaking Medicine News(10 mins):Health News:New E-health recommendations from ACP aim to improve health care quality, safety, and access 2Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:New Therapy Kills Human Leukemia Cells in Mice 2
...ts may be beneficial in preventing severe long-ter...resently there exists no effective treatment for t...isability is most likely to appear. The Children...ing in the Journal of Neuroscience, and conducted...
...C, Wednesday to demand more funds for cancer resea...traveled to the rally in Washington.// She said, "...hes so many people, but on the other hand, it's em...eople willing to volunteer, give their time and th...
...nesday reported having updated the warning label o...sers about the higher risk of blood clots from it....missioned study revealed that drug users faced two... lungs compared to women taking traditional birth-...
...rpose of a sunscreen lotion as well as offers prot...searchers//, well on the threshold of a discovery;...athway that will prevent the fair skin people from...ainst cancer. Study's lead author, Dr. David E. F...
Other Medicine News:Health News:Vitamin Shots to Combat MS Pain 2Health News:Contraceptive Patch Carries Risk of Blood clots 2
(Date:5/16/2008)... NEW YORK, May 16 /- Pulmo ...ounced details of the methodology and,purpose of i...ar Imaging,technology for the diagnosis of Pulmona... will be carried out by the Pulmo BioTech subsidia...s: "Phase I Study of the Use,of PulmoBind for Mole...
(Date:5/16/2008)... BRIDGEWATER, N.J., May 16 /- Data fr...ower mean baseline hemoglobin (Hb) levels,and the ...e effect of,restrictions on reimbursement for eryt...atients on the nation,s blood supply, will be pres... (ASCO) Annual Meeting later this,month. The meeti...
(Date:5/16/2008)...ktar,s Technology Enables First-Ever PEGylation of...ted Therapeutic Activity, SAN CARLOS, Calif., May...(Nasdaq: NKTR ) announced initial results today f...ecan. The data shows significant,anti-tumor activi...tudy,also demonstrates that Nektar,s small molecul...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8BioMarin to Present at the Rodman 26 Renshaw 9th Annual Healthcare Conference 1611 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 3US government delays nanotechnology safety measures 1048 1US government delays nanotechnology safety measures 1048 2Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 1Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 2
...FirstCall/ --,Bionovo, Inc.,s lead drug candidate,...eatment of hot flashes associated with menopause.,...he company,s,double-blind, placebo- controlled, ra...50 or more moderate to severe hot flashes,per week...receiving,MF101 (5 grams/day), MF101 (10 grams/day...
...rstCall/ -- VION,PHARMACEUTICALS, INC. announced t... session at the 43rd Annual Meeting of The America...anticancer agent,Cloretazine(R) (VNP40101M) as a s...elapsed or refractory small cell lung cancer. , Th...1M) in two,separate subpopulations of small cell l...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
The Mitek CuffTack sutureless fixation device offers superior fixation strength for rotator cuff repairs. The implant firmly reattaches soft tissue to the bone with one step insertion. CuffTack is in
...imple to use system can be used for open or arthro... a sterile disposable inserter. The unique deploym... insertion of the anchor into bone. The Independe...lows for the two pre-threaded sutures to independe...
The Micro Anchor is the smallest, strongest anchor on the market allowing exceptional flexibility in placement into even the smallest bones. This anchor comes pre-loaded with 3-0 or 4-0 ETHIBOND EXCE
FASTIN RC is a threaded titanium anchor, specifically designed for rotator cuff procedures. The anchor features wide threads and a small core to optimize bone purchase, as well as independent suture
Medicine Products: